Background: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is an increasingly recognized systemic autoimmune disease in the past decade, and encompasses a wide spectrum of disorders previously considered to be unrelated, but with common pathologic, serologic, and clinical features.There have been several hundred literatures on IgG4-RD published in the past few years, however, we still cannot well characterize this complicated disease, including clinical features, treatments as well as mechanisms, which promotesus to further describe this disease. Objectives: To describe the clinical presentations, laboratory features, imaging manifestations, treatments and evolutions in a cohort of 34 Chinese patients with immunoglobulin G-related diseases (IgG4-RD). Methods: A retrospective study was performed in Wuhan Tongji Hospital. Electronically stored records of clinical, laboratory, imaging, and histological features were reviewed. The diagnoses were made according to comprehensive diagnostic criteria for IgG4-RD. Disease activity was assessed by IgG4-RD Responder Index (RI).This study was approved by the Ethical Committee of TongjiHospital (TJ-C20150603). All patients were contacted, and consents were obtained from all the participants. Results: We found that among the whole 34 patients enrolled in this study (median age=51 years, male/female ratio=1.4/1), 65.2% tested patients had a declined HDL level, 82.3% tested patients had an elevated IgG4 level, and lymph node was the most frequently involved organ. 18F-FDG PET/CT had high sensitivity in providing information about the organ distribution of IgG4-RD. The IgG4 level and IgG4-RD RI in the multi-organs affected patients were significantly higher than that in the localized ones. Most patients were prescribed with glucocorticoids (GCs) alone or combined with disease modifying antirheumatic drugs (DMARDs), the majorities responded well, while some relapsed. Patients given rituximab (RTX) obtained good responses. 18 F]fluoride uptake was quantified in PET positive (PET + ) lesions using the standardized uptake value corrected for individual integrated whole blood activity concentrations (SUV AUC ). Clinical response to TNFi was defined according to ASAS20 at 24 weeks. Results: At baseline, in all patients at least one axial PET + lesion was found. In spine, 6/10 patients showed 84 lesions (range 2-30;63% thoracic spine, primarily costovertebral joints) and in the SI joints in 9/10 patients were PET + (Fig A) . Histological analysis of PET + lesions in the spine confirmed local osteoid formation, which was nearly absent in PET negative lesions. Quantitative PET analysis revealed significantly lower [
18 F]fluoride uptake in spine lesions at baseline in responders than in non-responders. This difference remained after 12 weeks of treatment (mean difference in SUV AUC : -0.5, 95% CI: [-0.7,-0 Background: Neuropsychiatric manifestations are common in patients with systemic lupus erythematosus (SLE). Furthermore, subclinical brain damage occurs in an even higher fraction of patients. However, little is known about the effect of these phenomena on brain connectivity. MRI-based connectomics relies on graph analysis of structural and functional images to detect alterations of the topographic organization of the brain and has been successfully employed to dissect network disassembly in neuroinflammatory diseases such as multiple sclerosis (MS) and Devic's syndrome. Objectives: To investigate the topographic organization of the brain of patients with SLE with and without neuropsychiatric manifestations. Methods: Thirty-two patients with SLE (12 with overt neuropsychiatric involvement as per ACR criteria) were enrolled and compared with 32 healthy controls (HC) and 32 patients with relapsing-remitting MS, all matched for sex, age and disease duration (where applicable). Diffusion tensor (DT) and dual-echo MRI scans were obtained. Structural connectivity matrices between 116 cortical and subcortical brain regions were estimated and global and nodal network metrics were calculated. Results: Conventional MRI revealed that patients with SLE had significantly higher T2-lesional volumes when compared to controls (p<0.0001). Patients with definite NPSLE had a higher lesion burden (p=0.006). Network strength, transitivity and global efficiency were all significantly impaired in patients with MS and SLE when compared to HC (p<0.0001). MS and SLE were also characterized by higher average path length when compared to HC (p<0.0001). Global structural alterations were more significant in MS patients than in patients with SLE (p from 0.005 to 0.01 at multiple comparison). However, antiDNA-positive patients (n=24) showed a more severe phenotype when compared to antiDNA-negative patients (p from 0.026 to 0.041) and did not differ significantly from patients with MS. When regional hubs were analysed, patients with SLE and MS showed a reduced strength compared to HC (p from <0.0001 to 0.001 at multiple comparison). Hub strength impairment was more pronounced in MS when compared to SLE and preferentially involved hubs located in fronto-temporo-parieto-occipital cortices, subcortical nuclei (including the thalamus, caudate nucleus and putamen) and cerebellum (p from 0.001 to 0.05 at multiple comparison). No significant associations were found between global structural parameters, clinical diagnosis of neuropsychiatric SLE, other SLE sub-phenotypes, presence of antiphospholipid antibodies, antiphospholipid syndrome and SLE-related damage burden. Conclusions: Structural alterations of global and regional brain connectivity occur in patients with SLE, irrespectively of the clinical phenotype. AntiDNA-positive patients are characterized by a more severe phenotype, which is similar to that of patients with relapsing-remitting MS. 
